Clinical characteristics of study participants
| Participant characteristics | Frequency (n=2885) | Percentage (%) |
| BMI (kg/m2) | ||
| Mean±SD | 24.41±5.35 | |
| Underweight (<18.5) | 236 | 9.39 |
| Normal (18.5–24.9) | 1310 | 52.15 |
| Overweight (25–30) | 583 | 23.21 |
| Obesity (>30) | 383 | 15.25 |
| Type of HIV | ||
| HIV-1 | 2435 | 96.93 |
| HIV-2 | 15 | 0.60 |
| HIV1/HIV2 | 62 | 2.47 |
| ART status | ||
| ART naive | 260 | 10.35 |
| On ART | 2252 | 89.65 |
| Period of HIV infection | ||
| Median (LQ–UQ) | 4.77 (2.30–5.40) | |
| <5 years | 1158 | 46.67 |
| 5–10 years | 717 | 28.90 |
| >10 years | 606 | 24.43 |
| Duration on ART | ||
| Median (LQ–UQ) | 4.35 (2.70–5.00) | |
| <5 years | 988 | 45.93 |
| 5–10 years | 706 | 32.82 |
| >10 years | 457 | 21.25 |
| NRTI regimen | ||
| Tenofovir based | 2489 | 99.08 |
| Abacavir based | 6 | 0.24 |
| Zidovudine based | 17 | 0.68 |
| Blood pressure | ||
| Normal | 1689 | 67.24 |
| Abnormal | 823 | 32.76 |
| Individual MetS components | Median (LQ–UQ) | |
| Waist circumference (cm) | 77.00 (62.00, 87.00) | |
| Fasting blood sugar level (mmol/l) | 5.70 (5.20, 6.30) | |
| HDL cholesterol (mg/dL) | 1.50 (1.20, 1.80) | |
| Triglycerides (mg/dL) | 0.87 (0.66, 1.18) | |
| Systolic blood pressure mm Hg | 118.00 (107.00, 132.00) | |
| Diastolic blood pressure mm Hg | 76.00 (69.00, 85.00) | |
ART, antiretroviral therapy; BMI, body mass index; HDL, high-density lipoprotein; LQ, lower quartile; MetS, metabolic syndrome; NRTI, nucleoside-reverse-transcriptase-inhibitor; UQ, upper quartile.